SHAH ALAM: Sunzen Biotech Bhd hopes to achieve record earnings for this financial year (FY22), underpinned by strong demand in its loan financing and traditional Chinese medicine (TCM) segments, said group managing director Teo Yek Ming.

The group posted its highest ever profit of RM3.64 million in FY17

Teo said the group will focus on these two segments, concentrating on its health and wellness subsidiary Ecolite and financing arm Finsource Credit respectively.